These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
Last week shows that oil prices are not the indicator for Middle East tensions they once were, and worries about global demand and growing U.S. production has changed that...Market Insiderread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Weather & Natural Disastersread more
Gluskin Sheff's David Rosenberg is painting a painful picture for stocks as earnings season goes into full gear.Futures Nowread more
On Saturday, Disney's Marvel Studios announced its upcoming slate of superhero films during a panel at San Diego Comic-Con.Entertainmentread more
The biotechnology sector took a hit after Democratic presidential nominee Hillary Clinton tweeted about the recent price hikes on EpiPens.
Earlier in the session, the iShares NASDAQ Biotechnology ETF (IBB) gained about 1 percent, but reversed its course after Clinton's tweet. The IBB fell 3 percent, its worst performance since June 27.
The sector has suffered from headline risk on the campaign trail ever since Clinton tweeted that she plans to tackle "price gouging" in the pharmaceutical industry.
Buyout chatter and optimistic trial results had initially boosted the sector.
The IBB was helped by shares of Sarepta Therapeutics and Incyte, which had gained as much as 9 percent and 7 percent, respectively. Those stocks have since pared their gains. Sarepta ended the day slghtly lower while Incyte was still modestly higher on the day.
In early trading, Insys Therapeutics shares jumped as much as 12 percent after the company reported statistically significant results for a phase 3 trial of its Sublingual Buprenorphine Spray. The study found that patients that used Insys' product had the greatest reduction in pain.
Insys CEO John Kapoor said that the company's "Buprenorphine Sublingual Spray could be a potentially useful drug for the treatment of moderate to severe pain and provide a valuable treatment option in a variety of clinical settings." Kapoor also said Insys will discuss the results with the FDA by the end of the year and is moving towards filing a new drug application.
After Clinton's tweet, Insys shares gave up their gains and ended the session 4 percent lower.
Shares of PharMerica also surged 13 percent after Reuters, citing people familiar with the matter, reported that the U.S. pharmacy manager is exploring strategic alternatives, including a potential sale.
— CNBC's Chris Hayes contributed to this report.